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group with AO; and between AO groups within overweight sub-
group overall and within genders. RESULTS: Baseline analysis
was conducted in overweight/obese subjects (BMI > or =
25kg/m2) with AO (n = 674, male 42%, female 58%, mean age
50, 91% Caucasian) and without AO (n = 293, male 73%,
female 27%, mean age 50, 88% Caucasian). Overall, subjects
with AO reported a statistically signiﬁcantly (p < 0.05) lower
total score and lower scores in all 5 domains compared with sub-
jects without AO. In subjects with AO, women had statistically
signiﬁcant lower scores, for all domains and total score, com-
pared with men (p < 0.05). Overweight subjects (BMI 25–30
kg/m2) with AO (n = 220) also reported a statistically signiﬁ-
cantly (p < 0.05) lower total score compared with overweight
subjects without AO (n = 254), in the overall population, as well
as in women. In men, the only difference observed was in the
Physical Function score. CONCLUSION: AO was associated
with impaired HRQOL (assessed using the IWQOL-Lite) for
both men and women, with decreases for women being more
marked. The data obtained in this Internet-based cohort are con-
sistent with those from the literature.
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OBJECTIVES: To evaluate the impact of the ﬁrst selective
cannabinoid type 1 (CB1) receptor blocker, rimonabant, devel-
oped for the management of cardiometabolic risk factors, on
health related quality of life (HRQOL). METHODS: Over 6600
overweight/obese patients, with or without comorbidities were
randomized in double-blind, placebo-controlled, 2 ﬁxed doses (5
mg and 20mg), parallel-group clinical trials. Patients completed
the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) and
the Short-Form Health Survey (SF-36) questionnaires at baseline
and every 3 months up to 1 year. The IWQOL-Lite is a validated
31-item self-reported questionnaire speciﬁcally designed for
HRQOL assessment in obesity and comprises 5 domains and a
total score. SF-36 is a standardized generic HRQOL measure
used in general population (non-speciﬁc for obesity). Analyses
presented were performed on mean score changes from baseline
to 1 year in the intent-to-treat population. RESULTS: At 1 year,
patients administered rimonabant 20mg once daily reported
consistently greater improvement in IWQOL-Lite scores than
patients in the placebo group in all domains (Physical Function,
Self-esteem, Sexual Life, Public Distress, Work) and total score
(p < 0.001, except Work, p = 0.03). SF-36 provided statistically
signiﬁcant results for 5/8 domains (p < or = 0.05); 3 of them
(Physical Functioning, Bodily Pain, General Health) supported
greater improvement with rimonabant, while the other 2 (Role
Emotional and Mental Health) were less decreased with placebo.
Overall, HRQOL results appeared to be less clinically meaning-
ful on the SF-36 [effect sizes (ES) ranging between 0.01 and 0.33,
depending on the score considered] than on the IWQOL-Lite (ES
between 0.22 and 0.45). CONCLUSION: Using an obesity-
speciﬁc questionnaire (IWQOL-Lite), rimonabant 20mg was
associated with a signiﬁcant and sustained improvement in
HRQOL up to 1 year. As expected, SF-36 appeared to be less
sensitive to clinical changes in this overweight/obese population.
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OBJECTIVES: Recent studies have suggested that use of inhaled
corticosteroids (ICS) may improve survival in COPD, particularly
when combined with a long-acting beta agonist (LABA).
However, the methods used to conduct these retrospective studies
have been questioned and none have examined what effect the
newer combination ICS/LABA inhalers may have on survival. The
goal of this project was to further examine the relationship
between ICS treatment, with or without LABA, and survival in
COPD. METHODS: COPD patients were identiﬁed from the
administrative databases of four different managed care pro-
grams: Lovelace Health Plan (Albuquerque NM), Health Part-
ners Health System (Minneapolis/St Paul MN), Henry Ford
Health System’s Alliance Plan (Detroit MI), and Harvard Pilgrim
Health Care (Boston MA). All patients who were diagnosed with
COPD between September 1, 2000 and August 31, 2001 and who
had at least 3 months treatment with either ﬂuticasone/salmeterol
(ADVAIR, N = 866), some other ICS/LABA (N = 525), ICS alone
(N = 742), LABA alone (N = 531), or a short-acting bron-
chodilator alone (SABD, N = 1832), were included. RESULTS:
In the basic Cox proportional hazards models, use of ADVAIR,
ICS/LABA, and ICS alone had signiﬁcant survival beneﬁts as com-
pared to SABD alone, after adjustment for differences in age,
gender, comorbidities, asthma status, and disease severity (HRs
0.638, 0.603, and 0.784, respectively, p < 0.05). Propensity score
matching to reduce the clinical differences between the treatment
groups versus the SABD reference groups found very similar
results. Nested case-control matching based on survival status
continued to show a highly signiﬁcant survival beneﬁt for
ADVAIR; other treatments also had favorable RR that did not
reach statistical signiﬁcance. CONCLUSIONS: Treatment with
ADVAIR or another ICS with or without LABA is associated with
improved survival in COPD. The treatment beneﬁt seen with
ADVAIR is robust to a number of analyses designed to adjust for
differences in clinical parameters and bias by indication.
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OBJECTIVES: Bronchodilators, including anticholinergics, are
central to the management of COPD. Current guidelines recom-
mend the use of bronchodilators in the management of mild to
moderate COPD and inhaled corticosteroids for severe patients
and patients with repeated exacerbations. This analysis evaluates
COPD patients treated with an inhaled corticosteroid or an anti-
cholinergic to determine the difference in treatment patterns and
costs between the two groups. METHODS: In a retrospective
database study, continuously enrolled patients aged 18 years and
older with a COPD diagnosis (COPD only or COPD+asthma),
